Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Better Than Short-term ADT With Salvage RT (LOBSTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04242017
Recruitment Status : Not yet recruiting
First Posted : January 27, 2020
Last Update Posted : January 27, 2020
Sponsor:
Collaborator:
Ipsen
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

Brief Summary:
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after radical prostatectomy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Triptoreline Phase 2 Phase 3

Detailed Description:

Radical prostatectomy (RP) is one of the standard treatment options for localized and locally advanced prostate cancer. RP should be combined with an extended pelvic lymph node dissection (ePLND) when the risk of pelvic involvement becomes substantial, at least 7%. In case of node-negative disease (pN0), adverse pathological features at examination of the RP-specimen such as extra-capsular extension (ECE), seminal vesicle invasion (SVI) and positive surgical margins (PSM) increase the risk of biochemical relapse (BR) and/or isolated local relapse (LR). Both a BR and LR, if not adequately treated, can finally result in the development of distant metastasis.

In case of BR and/or LR, salvage radiotherapy (SRT) is the only treatment option with curative intent. Several factors play a significant role in predicting the outcome after SRT: Gleason score, pre-SRT PSA, pre-SRT doubling time, SVI, SRT dose and duration of adjuvant androgen deprivation therapy (ADT) associated with SRT. The 2 latter variables have never been tested in a randomized controlled trial. The GETUG-AFU 16 trial randomized between no vs. 6 months ADT while patients received 66 Gy to the prostate bed and 46 Gy to the pelvis. Moreover, the pN0 status was not needed for inclusion. Also the RADICALS trial is currently running this comparison with a radiation dose of 66 Gy to the prostate bed and also no information on pN status is needed to be included in this study. In the LOBSTER study, the pN0 status is obligatory and the prescription dose is set at 70 Gy to the prostate bed and seminal vesicles. These conditions make this study unique compared to other already conducted and currently running trials.

In previous work, it has been demonstrated that ADT, added for 6 months to SRT, significantly improved biochemical relapse free survival at 5 years. Added to this, there is recent evidence that using a longer schedule of adjuvant ADT might be beneficial when compared to a 6-months schedule. Unfortunately, none of these suggestions are based on evidence coming from a randomized controlled trial.

Therefore, this randomized phase 2 trial 'LOBSTER' is conducted, comparing 6 versus 24 months of adjuvant ADT together with high-dose SRT in case of BR after RP in pN0 prostate cancer patients

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 394 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized controlled trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Prospective Phase II Trial to Assess the Effect of Short- Versus Long-term Adjuvant ADT With High Dose Salvage Radiotherapy on Distant Metastasis Free Survival in Patients With Biochemical Relapse After Radical Prostatectomy
Estimated Study Start Date : February 1, 2020
Estimated Primary Completion Date : February 1, 2024
Estimated Study Completion Date : February 1, 2029

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: salvage RT + 6 months ADT
70 Gy to the prostate bed (2 Gy/fraction) + 6 months ADT
Drug: Triptoreline
Comparison of the duration of ADT (Triptoreline)

Experimental: salvage RT + 24 months ADT
70 Gy to the prostate bed (2 Gy/fraction) + 24 months ADT
Drug: Triptoreline
Comparison of the duration of ADT (Triptoreline)




Primary Outcome Measures :
  1. Metastasis-free survival [ Time Frame: 5 years ]
    Time to appearance of M1a-b-c disease. In order to assess the absence/presence of M1a-M1c disease as early as possible, top-of-the-line imaging will be conducted in case of BR during follow-up after SRT and after agreement of the multidisciplinary uro-oncology team. Time point zero is the last day of radiotherapy (also applies for secondary endpoints). Top of the line imaging includes: CT thorax abdomen and bone scintigraphy (standard). PSMA PET-CT is allowed but not obligatory. Patients who are also included in the diagnostic imaging study are required to receive a PSMA PET-CT. Whole body MRI is allowed but not obligatory. BR is defined as any rise in PSA above the level of 0.2 ng/ml after a postradiotherapy nadir or a continued rise in the serum PSA despite salvage treatment (3). In case a BR is not accompanied by metastatic progression, PSMA PET/CT will be repeated every 6 months or earlier in case of prostate cancer-related symptoms.


Secondary Outcome Measures :
  1. Pelvic recurrence-free survival [ Time Frame: up to 10 years after randomization ]
    time to appearance of local recurrence (prostate bed) and/or N1 disease (positive lymph node(s) below the aortic bifurcation) using PSMA PET/CT and triggered by biochemical relapse.

  2. Clinical progression-free survival [ Time Frame: up to 10 years after randomization ]
    time to appearance of any recurrence (local recurrence, N1 (positive lymph node(s) below the aortic bifurcation), M1a-c disease) and triggered by biochemical relapse.

  3. (Palliative) Systemic therapy-free survival [ Time Frame: up to 20 years (or more) after randomization ]
    time to the start of palliative ADT

  4. Time to CRPC [ Time Frame: up to 20 years (or more) after randomization ]
    time to biochemical and/or clinical progression at castrate testosterone levels (<50 ng/dl). Progression is defined as three consecutive PSA rises (1 week interval), of which at least 2 rises with a PSA level of > 2 ng/ml and a rise of 50% of the nadir PSA level, progression of bone lesions (2 or more new bone lesions detected on bone scan), progression of soft tissue lesions according to RECIST criteria or the appearance of one or more new visceral or soft tissue (inclusive lymph node) metastasis.

  5. Cause-specific survival (CSS) [ Time Frame: up to 20 years (or more) after randomization ]
    freedom from dying from prostate cancer (K-M statistics)

  6. Overall survival (OS) [ Time Frame: up to 20 years (or more) after randomization ]
    freedom from dying from any cause (K-M statistics)

  7. Acute toxicity [ Time Frame: during RT, up to three months after radiation therapy ]
    adverse effects according to the CTCAE version 4.0

  8. Late toxicity [ Time Frame: starting from more than three months after radiation therapy, up to 5 years after radiotherapy ]
    adverse effects according to the CTCAE version 4.0

  9. Quality of life assessment [ Time Frame: up to 5 years after randomization ]
    EORTC QLQ-C30

  10. Quality of life assessment [ Time Frame: up to 5 years after randomization ]
    EORTC QLQ-PR25

  11. Quality of life assessment [ Time Frame: up to 5 years after randomization ]
    EQ-5D-5L



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of histologically proven prostate cancer, treated with RP and ePLND. All patients have to be pN0. The minimal template for ePLND is defined as the removal of the external iliac, internal iliac and obturator nodes (standard template). Removal of the presacral and common iliac nodes is left at the discretion of the treating urologist.
  • Asymptomatic PSA-rise post-RP, defined as a value equal to or more than 0.2µg/l and at least confirmed once (interval ≥2 weeks, confirmation PSA level should be higher). In case of Gleason 8-10, pT3b or R1 resection, an asymptomatic PSA-rise post-RP starting from ≥0.15 µg/l is allowed for inclusion. If the PSA-level is less than 0.4 ng/ml, no additional staging for distant metastasis is required before inclusion in the trial. The patient will be offered the opportunity to participate in a diagnostic sub-study with investigational imaging with 18F PSMA PET CT. However in case of PSA-level >0.4 ng/ml, biological imaging using 18F-PSMA or 68Ga-PSMA is mandatory as this is not considered investigational anymore. Therefore the patient cannot anymore take part in the diagnostic sub-study and (un-blinded) PET-CT is obligatory to rule out lymph node (N) and /or distant metastasis (M1a-c) before inclusion.
  • Testosterone levels within above 150 ng/dl.
  • ECOG 0-1
  • Life expectancy more than 5 years
  • Signed informed consent

Exclusion Criteria:

  • Presence of pN1 disease at original surgical specimen.
  • Presence of distant metastasis at time of referral (M1a-c). If PSA more than 0.4 ng/ml, imaging with PET-CT is required to rule out distant metastasis (see above). Other additional imaging modalities (CT scan, bone scintigraphy...) are allowed but left at the discretion of the treating centre.
  • Undetectable PSA (less than 0.2 ng/ml) at time of referral.
  • Previous RT making new RT impossible (overlapping treatment fields).
  • Known contraindications to irradiation (Ulcerative Colitis, Crohn Disease, Ataxia Teleangiectasia…)
  • Active treatment with ADT or PSA modulating drugs (finasteride, dutasteride, high-dose corticoids…)
  • Not able understanding treatment protocol or signing informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04242017


Contacts
Layout table for location contacts
Contact: Charlien Berghen, MD 003216345217 ext 003216345217 charlien.berghen@uzleuven.be
Contact: Gert De Meerleer, MD, PhD 003216347600 ext 003216347600 gert.demeerleer@uzleuven.be

Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Ipsen
Investigators
Layout table for investigator information
Study Chair: Gert De Meerleer, MD, PhD UZ Leuven
Layout table for additonal information
Responsible Party: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT04242017    
Other Study ID Numbers: S61996
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Universitaire Ziekenhuizen Leuven:
pN0
biochemical recurrence
salvage radiation therapy
hormonal treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents